Bactiseal Catheter Safety Registry in China

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-09-01

Study Completion Date

2020-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Research Purpose: This study aimed to continue to evaluate safety information from subjects implanted with a catheter (trade name: Bactiseal) produced by Codman \& Shurtleff, Inc. of the United States. Device safety would be assessed based on all the adverse events that occurred within one year after the subjects implanted the catheter.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bactiseal Catheter Safety Registry Study

NCT06276543

Hydrocephalus

RECRUITING

Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

NCT05397106

Hydrocephalus Hydrocephalus in Children NPH (Normal Pressure Hydrocephalus) +4 more

RECRUITING

Cera™ VSD Occluder Post Market Clinical Follow-up

NCT05939713

Ventricular Septal Defect

COMPLETED

Study to Evaluate the Safety and Effectiveness of the CODMAN ENTERPRISE® Vascular Reconstruction Device

NCT02532517

Intracranial Aneurysm

TERMINATED NA

Self-Centering Guide Catheter Feasibility Study

NCT02639494

Aortic Stenosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study aimed to continue to evaluate safety information from subjects implanted with a catheter (trade name: Bactiseal) produced by Codman \& Shurtleff, Inc. of the United States. Device safety would be assessed based on all the adverse events that occurred within one year after the subjects implanted the catheter.

This study was designed to be single arm, multi-center, and retrospective. A total of 50 patients would be retrospectively enrolled. Information would be collected on adverse events of subjects enrolled within one year after the implantation of the Bactiseal Catheter from August 07, 2018 to Novemver 30, 2020.

The following information would be collected from subjects' medical records or hospitals' databases (if any):

1. General condition of the subjects
2. Intraoperative condition and catheter implantation
3. Information on the shunt product
4. Adverse events of subjects within one year after the operation and classification of the adverse events
5. Relevant examinations in case of postoperative infection
6. Other adverse event-related information (except anticipated adverse events)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hydrocephalus

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bactiseal Catheter

Bactiseal Catheter manufactured by Codman \& Shurtleff, Inc. in the United States is a silicon catheter impregnated in rifampicin and clindamycin.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The informed consent was exempted by the Ethics Committee of a research center. Either a subject or his/her legal representative signed the informed consent form (ICF) prior to enrollment.
* A subject had an indication suitable to use Bactiseal Catheter.
* A subject received a hydrocephalus shunt at least one year ago.

Exclusion Criteria

* A subject didn't have an indication suitable to use the product.
* A subject was known to be allergic to a component or ingredient of the product to be implanted, including silicone tubing, rifampicin, and clindamycin.
* According to the comprehensive judgment of an investigator, a subject had an infection of the implant site when the shunt was implanted, such as ventriculitis, meningitis, peritonitis, and local implant skin infection.
* A subject was simultaneously implanted with another shunt system different from Bactiseal Catheter.
* A subject had a contraindication of the shunt operation.
* A subject had uncorrected coagulopathy or any bleeding disorder.

Eligible Sex

ALL

Accepts Healthy Volunteers

No